Color Code
Brown

Pneumococcal Conjugate Vaccine Surveillance and Evaluation in Burkina Faso

1050
infectious disease
Pneumococcal Conjugate Vaccine Surveillance and Evaluation in Burkina Faso
Burkina Faso
To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

Healthy Homes, Healthy People on the Navajo Nation

1042
america
Healthy Homes, Healthy People on the Navajo Nation
United States of America
To reduce the incidence of the rodent-borne disease hantavirus among residents of the Navajo Nation by preventing exposure to the virus through empowering residents to repair and reinforce their homes against rodents, notably deer mice, the vector species for hantavirus.

Evelyn and Thomas McKnight Family Fund for Patient Safety

patient safety
Evelyn and Thomas McKnight Family Fund for Patient Safety
safe healthcare
United States of America
To honor and recognize important work to promote safe injection practices and patient safety and produce educational materials that raise awareness and highlight the work of the One & Only Campaign.

History, Immunity and Transmission Patterns of Sapovirus

1039
infectious disease
History, Immunity and Transmission Patterns of Sapovirus
United States of America
To conduct a birth cohort study in Nicaragua to better understand the epidemiology, immunity and transmission patterns of sapovirus using next-generation sequencing strategies.

National Introduction of HPV Vaccine Evaluation

1030
infectious disease
National Introduction of HPV Vaccine Evaluation
Senegal
United States of America
Zimbabwe
To capture the successes and challenges that arise with a national introduction of the HPV vaccine in low-and lower-middle income countries and to gain a better understanding of program transition to national scale-up, program preparation and communication, program delivery and financial implications for long-term sustainability.

Immunologic Endpoints Against Young Infant Group B Streptococcal Disease

1029
infectious disease
Immunologic Endpoints Against Young Infant Group B Streptococcal Disease
United States of America
To provide a case-control study comparing naturally occurring group B strep antibodies in young infants with invasive disease versus controls will establish antibody thresholds associated with protection and inform decisions about future maternal Group B Streptococcus vaccine licensure.
Subscribe to Infectious Disease